Telix Pharmaceuticals has appointed Grupo RPH as CMO and product distribution partner for Brazil. The partnership will initially focus on imaging prostate cancer but is structured to be able to include other Telix products in the future, including therapeutics.
Telix is a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR).
Reflecting this focus, Grupo RPH is the owner of the only private-owned fully GMP nuclear medicine production facility in Brazil. This local production will be an advantage for Australia-based Telix.
Rafael Madke, Grupo RPH Managing Director, said: “Telix’s rapid growth over the past 12 months has been impressive, with a promising product portfolio for the Latin American market. With the strong position of Grupo RPH in Brazil and our extensive capability to manufacture and distribute nuclear medicine products, we aim to support Telix’s commercial objectives in a cost and operationally-effective way for our region."
Telix Pharmaceuticals VP of Corporate Development, Ludovic Wouters, said: “This partnership with Grupo RPH opens us a large and rapidly-growing market for gallium-68 based radiopharmaceuticals. We are delighted to be working work such a capable partner to bring our prostate imaging technology to the LATAM market, with the potential of other product collaborations in the future.”
The agreement grants exclusive right for the manufacturing and distribution of the TLX591-Cdx (68Ga-PSMA-11) cold kit for the Brazilian market. This will be the first product the partnership will give attention to.
